Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
PMID: 32198149

Abstract

PURPOSE: Using standard-of-care CT images obtained from patients with a diagnosis of non-small cell lung cancer (NSCLC), we defined radiomics signatures predicting the sensitivity of tumors to nivolumab, docetaxel, and gefitinib.

Authors

  • Laurent Dercle
    Department of Radiology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032; Gustave Roussy, Université Paris-Saclay, Université Paris-Saclay, Département D'imagerie Médicale, Villejuif, France.
  • Matthew Fronheiser
    Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey.
  • Lin Lu
    School of Economics and Management, Guangxi Normal University, Guilin, China.
  • Shuyan Du
    Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey.
  • Wendy Hayes
    Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey.
  • David K Leung
    Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey.
  • Amit Roy
    Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Lawrenceville, New Jersey, USA.
  • Julia Wilkerson
    The National Cancer Institute, NIH, Bethesda, Maryland.
  • Pingzhen Guo
    Department of Radiology, Columbia University Medical Center/New York Presbyterian Hospital, New York, New York.
  • Antonio T Fojo
    Columbia University/New York Presbyterian Hospital and James J. Peters VA Medical Center, New York, New York.
  • Lawrence H Schwartz
    Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
  • Binsheng Zhao
    Department of Radiology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032.

Keywords

External Resources

Popular Topics
Recent Journals